Key Developments For Sinovac Biotech Ltd
Sinovac Biotech Ltd (SVA.O) (Consolidated Issue listed on NASDAQ Global Market)
Sinovac Biotech Ltd. Files Shelf Registration Statement
Sinovac Biotech Ltd. announced that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. If and when the shelf registration statement on Form F-3 is declared effective by the SEC, Sinovac may from time to time offer and sell up to 10 million common shares. The use of the net proceeds from the sale of the common shares will be set forth in the applicable prospectus supplement filed each time common shares are sold.
Sinovac Biotech Ltd.'s PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
Sinovac Biotech Ltd. announced that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company's H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.
Sinovac Biotech Ltd. Receives Purchase Order From Shanghai Government To Supply Hepatitis A Vaccine Healive
Sinovac Biotech Ltd. announced that it was selected by the Shanghai Government to supply its inactivated hepatitis A vaccine, Healive, to the public market of Shanghai. Out of the five vaccine manufacturers that participated in the bidding process, the Shanghai Government awarded Sinovac Biotech Ltd. the entire hepatitis A vaccine purchase order, valued at RMB20.6 million, or approximately $3 million. Pursuant to the agreement, Sinovac Biotech Ltd. will supply Healive over the next twelve months. The purchase plan from the Shanghai Government reflects the continued expansion of government purchase programs for vaccines. This is part of the national expanded immunization program (EPI) funded by the Chinese government.
Sinovac Biotech Ltd. Reaffirms FY 2009 Revenue Guidance
Sinovac Biotech Ltd. announced that it remains on track to exceed the previously projected fiscal 2009 revenue range of $55-$60 million.
Sinovac Biotech Ltd. To Transfer Stock Exchange Listing To NASDAQ Global Market
Sinovac Biotech Ltd. announced that it will voluntarily transfer its stock exchange listing from the NYSE Amex to the NASDAQ Global Market. It is anticipated that Sinovac's common shares will commence trading on NASDAQ on or about November 16, 2009. Sinovac will continue to trade under the ticker symbol 'SVA.'
